Biomea Fusion, Inc. Stock Price, News & Analysis

Biomea Fusion (Nasdaq: BMEA) will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025 at 8:00 a.m. PT / 11:00 a.m. ET. A live audio webcast will be available via the company's Investors & Media site and a replay will be posted after the event. The company is a clinical-stage diabetes and obesity firm and will join the session as scheduled.

Investors can access the live audio webcast and subsequent replay at https://investors.biomeafusion.com/news-events/events.

Biomea Fusion (Nasdaq: BMEA) priced an underwritten public offering on Oct 7, 2025 consisting of 11,195,121 shares of common stock with accompanying warrants and up to 1,000,000 pre-funded warrants and accompanying warrants. An underwriter option covers up to 1,829,268 additional shares/warrants. Each share plus warrant is priced at $2.05; each pre-funded warrant plus warrant at $2.0499. Accompanying warrants are immediately exercisable at $2.50 and expire three years from issuance. Gross proceeds to the company are expected to be approximately $25.0 million, before fees and expenses, with closing expected on Oct 8, 2025 subject to customary conditions.

Biomea Fusion (Nasdaq: BMEA) announced on Oct 6, 2025 that it has commenced an underwritten public offering of its common stock and accompanying warrants, with pre-funded warrants offered to certain investors in lieu of common stock. The company said it will grant underwriters a 30-day option to purchase up to an additional 15% of the shares and/or warrants as overallotment. All securities in the proposed offering are to be sold by Biomea and the offering is subject to market and other conditions, with no assurance it will be completed on specific terms or timing.

The offering is being managed by Jefferies and will be made under an effective Form S-3 registration (filed Aug 5, 2025; declared effective Aug 15, 2025); a preliminary prospectus supplement will be filed with the SEC when available.

Biomea Fusion (Nasdaq: BMEA) reported positive 52-week results from its Phase II COVALENT-111 trial of icovamenib in type 2 diabetes, showing durable, post-treatment glycemic benefit and a favorable safety profile.

Key outcomes include a durable HbA1c reduction of 1.2% (p=0.01) in severe insulin-deficient patients through Week 52, a strongest Arm B effect of 1.5% (p=0.01, n=6), and a 1.3% (p=0.05, n=11) reduction at Week 52 in patients on GLP-1 therapy who had not reached targets. No treatment-related serious adverse events or discontinuations were reported. Planned Phase IIb and Phase II starts expected in Q4 2025. A conference call is scheduled for Oct 7, 2025, 8:30 AM ET.

Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has granted stock options to one new employee. The compensation committee approved non-qualified stock options to purchase 48,000 shares of common stock on September 24, 2025.

The stock options will vest quarterly over four years, with 1/16 of the shares vesting each quarter, contingent on continued employment. The grant was made under Biomea's 2023 Inducement Equity Plan, adopted on November 17, 2023, and complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement grant.

Biomea Fusion (NASDAQ:BMEA) presented promising preclinical data for its menin inhibitor icovamenib in combination with semaglutide at the 61st EASD Annual Meeting. The combination therapy demonstrated significant improvements in a Type 2 Diabetes animal model, including a 60% reduction in fasting blood glucose and 50% lower glucose AUC compared to semaglutide alone.

Key findings showed the combination achieved greater body weight reduction (-12.5% vs -3.4%) while preserving lean mass, and improved beta cell function. Additionally, Biomea announced FDA clearance of their IND for BMF-650, their oral GLP-1 receptor agonist, with Phase I obesity trial data expected in H1 2026.

The company plans to advance clinical evaluation of icovamenib with GLP-1 therapies in a Phase II study starting in H2 2025.

Biomea Fusion (Nasdaq: BMEA) reported Q2 2025 financial results and key developments for its diabetes and obesity pipeline. The company presented three significant studies at ADA 2025 highlighting icovamenib's therapeutic potential in type 2 diabetes, showing durable HbA1c reduction and improved beta-cell function. Their next-generation oral GLP-1 receptor agonist, BMF-650, demonstrated up to 15% weight reduction in non-human primates.

The company raised $42.8 million through a public offering, extending cash runway into H2 2026. Q2 2025 resulted in a net loss of $20.7 million, compared to $37.3 million in Q2 2024. Biomea reduced its workforce and expects quarterly operational expenses to be approximately 40% lower than the previous quarter.

Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has appointed Julianne Averill to its Board of Directors, effective July 22, 2025. Averill, who will serve on the Audit Committee, brings over 20 years of experience in life sciences and digital health, currently serving as Managing Director at Danforth Advisors.

The appointment comes as Bihua Chen steps down after more than four years on the board. Averill's expertise includes capital markets, M&A, and operational scale, with involvement in transactions exceeding $10 billion in aggregate value. She holds both B.S. and M.S. degrees from California State University, along with CPA licensure and NACD Directorship Certification.

Biomea Fusion (BMEA) presented promising new data for icovamenib, their oral menin inhibitor, at the ADA Scientific Sessions. In clinical trials, icovamenib demonstrated significant efficacy in type 2 diabetes treatment, achieving a 1.0% placebo-adjusted HbA1c reduction and 55% C-peptide increase in insulin-deficient patients. When combined with low-dose semaglutide in preclinical studies, the treatment showed superior metabolic benefits including enhanced glycemic control, 60% lower fasting blood glucose, and greater body weight reduction while preserving lean mass. The Phase II COVALENT-111 trial revealed sustained benefits even after treatment discontinuation, with particularly strong results in patients using GLP-1 RA therapy. The drug demonstrated good tolerability with no significant adverse events or discontinuations.